↑ 薬物リストへ　← 戻る

Emicizumab (ace910, ro5534262)    (DrugBank: Emicizumab)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
288自己免疫性後天性凝固因子欠乏症［自己免疫性出血病XIII (~2017.3)］1

288. 自己免疫性後天性凝固因子欠乏症［自己免疫性出血病XIII (~2017.3)］　［臨床試験数：189，薬物数：219（DrugBank：29），標的遺伝子数：18，標的パスウェイ数：26］
Searched query = "Autoimmune acquired coagulation factor deficiency", "Coagulation factor deficiency", "Factor XIII deficiency", "Factor VIII deficiency", "Acquired hemophilia A", "von Willebrand Disease", "Factor V deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 189 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-JapicCTI-205151
15/6/202007/02/2020PHASE III STUDY OF EMICIZUMAB IN PATIENTS WITH ACQUIRED HEMOPHILIA A (AGEHA)A MULTICENTER, OPEN-LABEL, NON-RANDOMIZED, PHASE III STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB IN PATIENTS WITH ACQUIRED HEMOPHILIA A Acquired hemophilia AIntervention name : emicizumab (ACE910, RO5534262)
INN of the intervention : emicizumab
Dosage And administration of the intervention : Emicizumab will be administered subcutaneously once weekly.
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -		Chugai Pharmaceutical Co., Ltd.NULLrecruiting18BOTH11Phase 3Japan